Nexalin Technology, Inc. is classed by the SEC under Electromedical & Electrotherapeutic Apparatus (industry code 3845), based in Houston, TX. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $302 thousand and a loss of $8 million (its filed statements).
Product businessElectromedical & Electrotherapeutic ApparatusHouston, TXfilings since 20117 of 9 filed, 2 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3845, Electromedical & Electrotherapeutic Apparatus); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.7 out of ten, 7 of 9 metrics filed and 2 estimated: past 2.8 out of ten, present 2.5 out of ten, future 6.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 2.2 out of ten. 10 warning events since 2017; the latest 2026-09-28. 22nd percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.3 out of ten. +20.3% a year over 5 filed years; profitable in 0 of 5. 33rd percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 2.8 out of ten. CrossAssetData estimate 2.8/10, confidence 35 of 100 (one part). 28th percentile among 27 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 3.6 out of ten. ROE -219%: lost 219¢ per shareholder dollar. Leverage 19%: owes 19¢ per asset dollar. 36th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 0.5 out of ten. bottom 5% of 24 in its family; net margin -2725.8%. 5th percentile among 24 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 3.4 out of ten. CrossAssetData estimate 3.4/10, confidence 35 of 100 (one part). 34th percentile among 25 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 5.6 out of ten. top 44% of 23 in its family for room to expand. 56th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.9 out of ten. top 41% of 25 in its family for growth drivers. 59th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 6.9 out of ten. top 31% of 20 in its family for expectations against reality. 69th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-25 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-12 for the period ended 2026-06-30 (on EDGAR). Newest filing: Form S-1/A, 2026-10-08. Filings on record since 2011. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Device Sales 45%, Equipment 30%, Licensing Fee 16%, Other 9%. By geography: International 63%, United States 37%. As tagged in its annual report (Form 10-K, filed 2026-03-25).
Who runs it
White, Mark (CEO); Van, Fleet Justin (CFO); Elson, Marilyn (Ms. Elson serves as CFO); Owens, David (Chief Medical Officer); Shelton, Carolyn Hamby (Sr. VP - Quality - Regulatory); Hu, Ben (director); Kazden, Alan (director). 7 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.